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ABSTRACT
Human T-cell lymphotropic virus type 1 (HTLV-1) is endemic in many parts of the world and is primarily transmitted through 
sexual intercourse or from mother to child. Sexual transmission occurs more effi ciently from men to women than women to men 
and might be enhanced by sexually transmitted diseases that cause ulcers and result in mucosal ruptures, such as syphilis, herpes 
simplex type 2 (HSV-2), and chancroid. Other sexually transmitted diseases might result in the recruitment of infl ammatory 
cells and could increase the risk of HTLV-1 acquisition and transmission. Additionally, factors that are associated with higher 
transmission risks include the presence of antibodies against the viral oncoprotein Tax (anti-Tax), a higher proviral load in 
peripheral blood lymphocytes, and increased cervicovaginal or seminal secretions. Seminal fl uid has been reported to increase 
HTLV replication and transmission, whereas male circumcision and neutralizing antibodies might have a protective effect. 
Recently, free virions were discovered in plasma, which reveals a possible new mode of HTLV replication. It is unclear how this 
discovery might affect the routes of HTLV transmission, particularly sexual transmission, because HTLV transmission rates are 
signifi cantly higher from men to women than women to men.
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INTRODUCTION
Human T-cell lymphotropic virus type 1 (HTLV-1) and 
human T-cell lymphotropic virus type 2 (HTLV-2) belong to the 
Retroviridae family and the genus deltaretrovirus. HTLV-1 and 
HTLV-2 were the fi rst retroviruses to be identifi ed in humans1,2. 
Two novel viruses, human T-cell lymphotropic virus type 3 
(HTLV-3) and human T-cell lymphotropic virus type 4 (HTLV-4), 
have recently been isolated in Central Africa; however, these 
viruses have not been associated with human disease3,4, and 
transmission among humans has not been demonstrated5.
HTLV-1 infection is endemic in many parts of world, 
including southwestern Japan, several Caribbean islands, 
South America, and locations in the Middle East and Australo-
Melanesia6,7. A recent review analyzed the epidemiological 
data from a total population of approximately 1.5 billion 
individuals who were residing in HTLV-1-endemic areas; the 
epidemiological data from other highly populated regions such 
as China, India, the Maghreb, and East Africa have not been 
analyzed. The fi ndings of this review suggested that there are 
approximately 5-10 million HTLV-1 carriers worldwide7. These 
results are consistent with previous estimates of 10-20 million 
infected individuals8. In Brazil alone, an estimated 2.5 million 
people are infected, which is most likely the largest number of 
seropositive individuals in a single country9.
The Human T-cell lymphotropic virus type (HTLV) retrovirus 
is the causative agent of HTLV-1-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP), adult T-cell leukemia (ATL), 
uveitis, infective dermatitis, inflammatory disorders, and 
emerging syndromes that are associated with HTLV6-9. 
HTLV-2, despite its close relationship to HTLV-1, has 
distinctive pathogenesis and transmission characteristics, such 
as a lower provirus load10,11, a higher occurrence of pneumonia 
and bronchitis12,13 and a similar prevalence in males and females, 
which suggests that sexual transmission of the virus might be 
equally effi cient between the sexes14. HTLV-2 is prevalent in 
native populations, such as indigenous peoples in the Americas 
and Pygmy tribes in Africa, and in intravenous drug users15-19. 
Despite a 65% homology with HTLV-1, HTLV-2 has not 
been consistently associated with human disease; however, 
neurological disorders similar to HAM/TSP have been observed 
in patients with HTLV-2 infection15,20.
Genome sequence analyses have subdivided HTLV-1 
and HTLV-2 into seven and four subtypes, respectively. The 
subtypes do not vary in pathogenicity and most likely refl ect the 
geographical origins and migrations of ancient populations21-23. 
In addition, genomic sequencing has confi rmed the transmission 
of HTLV-1 from infected spouses to uninfected spouses by 
revealing identical sequences in seropositive individuals and 
those spouses who seroconverted24. 
CELL-TO-CELL SPREAD: THE HTLV-1 
VIROLOGICAL SYNAPSE
The routes of transmission of HTLV-1 and HTLV-2 are 
identical to those of human immunodefi ciency virus (HIV); 
however, free infectious HTLV-1 particles are rarely found in 
plasma. Direct cell-to-cell contact is necessary for the effi cient 
transmission of HTLV-1 from an infected cell to a new host cell 
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via a specialized and highly organized mechanism known as the 
virological synapse, in which the virus subverts normal T cell 
physiology. Direct cell contact rapidly induces cytoskeleton 
polarization from the infected cell to the cell-cell junction. 
HTLV-1 core (Gag protein) complexes and the HTLV-1 genome 
accumulate at the cell-cell junction and are rapidly transferred 
to the uninfected cell, a process that requires approximately 
two hours25. Another possible route of in vivo intercellular 
HTLV-1 transmission involves the internalization of cell-free 
particles by dendritic cells, which are subsequently transferred 
to lymphocytes by cell-to-cell contact26. Additionally, virus 
particles might be retained on the cell surface in a biofi lm-like 
structure before being laterally transferred to recipient cells 
that are outside of cell-cell contact regions27. Whereas HTLV-1 
infects mobile cells (lymphocytes), the virological synapse 
maximizes transmission effi ciency and limits virus exposure 
to host defense mechanisms28.
MODES OF HTLV TRANSMISSION
Human T-cell lymphotropic virus transmission primarily 
occurs through the following three routes: 1) vertically from 
mother to child during transplacental transfer, delivery, or 
breastfeeding; 2) sexual contact, primarily from men to women; 
and 3) parenterally through the transfusion of blood and blood 
components or through contaminated needles (Figure 1).
The limited passage of infected lymphocytes through 
the placenta most likely contributes to the relative rarity of 
transplacental HTLV-1 infection29,30; however, this type of 
HTLV-1 infection requires further study to evaluate its effects 
on the fetus, which could have implications for counseling 
serologically discordant couples who wish to have children. 
HTLV-1 transmission occurs through the transfusion of cellular 
blood components, which results in seroconversion in more 
than 40% of recipients; the transfusion of plasma or plasma 
derivatives does not result in seroconversion31.
The highest prevalence of HTLV has been observed in 
injection drug users32,33. HTLV-1 is more frequent among 
injection drug users in Brazil and New York34-38, whereas HTLV-2 
is more prevalent in injection drug users in other locations in 
North America and in Europe39-44. In 2001, the fi rst cases of 
HTLV-1 transmission through organs that were transplanted 
from asymptomatic infected donors were reported in Europe; 
three donor organ recipients developed subacute myelopathy 
shortly after transplantation45. Pepin et al. postulated that 
iatrogenic HTLV-1 transmission occurred during massive 
intramuscular pentamidine interventions to control sleeping 
sickness in equatorial Africa from 1947-195346.
Lopes47 cited research that reported possible HIV transmission 
between two sisters in Sydney in 2003. One sibling was infected, 
and the other sibling was found to be positive when donating 
blood. Transmission was hypothesized to have occurred through 
a shared razor blade. Lopes considered this route of transmission 
to be a risk factor for HTLV-1 transmission in blood donors; 
however, few studies have been conducted on this subject to 
support these fi ndings47.
HTLV is present in the genital secretions of infected 
individuals and could be transmitted through sexual intercourse, 
which is the second most common mode of HTLV transmission48. 
Infection in endemic areas is maintained by horizontal 
transmission though unprotected sexual intercourse and by 
vertical transmission from mother to child during breastfeeding49.
SEXUAL TRANSMISSION
High-risk behaviors, such as unprotected sex50, multiple 
partners51-53, sexual intercourse with injection drug users34,39, 
sexual partners from HTLV-endemic areas54,55, certain sexual 
practices53, and a history of other sexually transmitted 
diseases50-60, have been identifi ed as risk factors for HTLV 
infection. In addition, the epidemiology of HTLV, particularly 
its tendency to occur in clusters, has enabled the identifi cation 
of groups who are at risk for exposure, including injection drug 
users34,56,59, sex workers50,55-62, men who engage in intercourse 
with other men52,53,56, recipients of blood transfusions in Brazil 
before November 199363, and sexual partners of known HTLV 
carriers64-66 (Figure 2).
HTLV-1 is transmitted more efficiently from males to 
females than from females to males. Research in Japan 
over a 10-year period demonstrated that the rate of HTLV-1 
transmission from husband to wife was 60.8%, whereas the 
rate of transmission from wife to husband was 0.4%64. Roucoux 
et al.65 performed a prospective study of 85 couples who were 
serodiscordant for both viruses (30 patients with HTLV-1 and 
55 patients with HTLV-2) over a 10-year period and found 
no signifi cant differences in the sexual transmission rates 
I. Vertical (mother to child)
A. breastfeeding
B. during delivery
C. transplacental
II. Parenteral
A. blood transfusion
B. injection drug use
C. organ transplantation
D. occupational accidents
E. Iatrogenic
F. razor blade sharing
III. Sexual
A. male to female
B. female to male
C. male to male
FIGURE 1 - Modes of HTLV-1 and HTLV-2 transmission. 
HTLV-1/2: human T-cell lymphotropic virus types 1 and 2. 
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I. Sociodemographic
A. live in or originate from an endemic area
II. Risk-associated exposures
A. unprotected sex
B. multiple sexual partners
C. sexual partnership with an injection drug user
D. sexual partnership with individuals from endemic areas
E. type of sexual practice
F. history of other sexually transmitted disease
III. Risk groups for exposure
A. injection drug users
B. sex workers
C. men who have sexual intercourse with other men
D. sexual partners of known HTLV carriers
IV. Biological
A. gender
male>female
B. age
>45 years
C. hormonal
menopause
D. high circulating proviral load
>60 years
HTLV-1-associated myelopathy/
tropical spastic paraparesis
infective dermatitis
adult T-cell leukemia-lymphoma
HTLV-1 uveitis
V. Co-infections
A. strongyloidiasis
B. sexually transmitted disease 
FIGURE 2 - Factors that might infl uence the risk of sexual 
transmission or acquisition of HTLV. 
HTLV-1: human T-cell lymphotropic virus type 1.
between HTLV-1 and HTLV-2 (0.9 and 0.4 transmissions per 
100 person-years (py) for HTLV-1 and HTLV-2, respectively). 
The male to female transmission rate for HTLV-1/2 was 1.2 
transmissions/py, whereas the female to male transmission rate 
was 0.4 transmissions/py.
The results of this study are in contrast to the fi nding of 2.5 
transmissions/100py by Stuver et al.66 in a Miyazaki cohort of 
southeastern Japanese couples; however, Roucoux et al. included 
a higher number of couples with HTLV-1 infections that were, 
on average, much older and in longer relationships (>360 vs. 
72 months). Larsen et al.67 reported an overall HTLV prevalence 
of 3.6% (76 of 2,127 subjects) in an adult population living in 
urban areas in Guinea-Bissau, Africa, and the prevalence rates 
among men and women were 2.2% and 4.7%, respectively. This 
difference increased with age (>44 years).
Murphy et al.51 found lower effi ciency in female-to-male 
HTLV-1 sexual transmission in 2,050 consecutive patients who 
presented with new episodes of sexually transmitted disease. 
Additionally, they found that penile ulcers or concurrent syphilis 
might increase the risk of infection in men.
In a multivariate analysis of HTLV transmission in Salvador, 
Bahia, Dourado et al.34 concluded that sexual transmission 
might play an important role in the increasing rates of HTLV 
transmission from men to women among intravenous drug users 
in endemic areas, in which HTLV infection rates remain high. 
They reported that the prevalence rates of HTLV-1, HTLV-2, 
and HIV-1 were 22%, 11.3% and 44.1% among men and 46.2%, 
10.3%, and 74.4% among women, respectively.
Gottuzo et al.50 found that the prevalence of HTLV-1 in 
400 female sex workers in Peru who were treated in clinics for 
sexually transmitted diseases increased with the duration of 
prostitution from 3.6% (<3 years) to 9.3% (3-6 years) to 15.9% 
(>6 years). Wignall et al.62 reported a 21.8% prevalence rate of 
HTLV-1 among prostitutes in Callao, Peru, which was correlated 
with the number of years of prostitution; this fi nding suggests an 
association between sexual activity and HTLV-1 transmission. 
Nakashima et al.58 found a signifi cantly higher prevalence of 
anti-HTLV-l antibodies (5.1%) in 409 female prostitutes in 
Kyushu, Japan than in a control group of non-prostitutes (1.3%). 
Additionally, they reported that the participants, who were 
initially seronegative, seroconverted over the 2-year study period.
Khabbaz et al.59 found anti-HTLV-1/2 seroprevalence 
rates that ranged from 0%-25.4% among 1,305 female 
prostitutes from eight areas in the United States, and the overall 
prevalence was 6.7%. In this study, HTLV-1/2 seropositivity 
was independently associated with race, intravenous drug use, 
hepatitis B seropositivity, the area of recruitment (Newark, 
NJ, USA), and the years of sexual activity. The authors could 
not differentiate between HTLV-1 and HTLV-2 seroreactivity; 
however, the seropositivity rate among women with no admitted 
intravenous drug use and no needle marks (2.4%) was high 
compared with the reported rates in other groups in the USA.
Verdier et al.60 conducted a serological survey of 3,177 Ivory 
Coast residents and observed an HTLV-1 prevalence of 7.4% in 
prostitutes. They concluded that this high HTLV-1 prevalence 
suggests that heterosexual contact is involved in HTLV-1 
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transmission and that prostitutes might play an important role 
in the spread of HTVL in Africa.
The rate found by Verdier et al.60 is similar to that found by 
Delaporte et al.57 in another African population in Kinshasa, 
Zaire. Among 1,183 prostitutes, 86 (7.3%) were positive for 
HTLV-1. The seroprevalence among prostitutes from equatorial 
regions was 12.7% compared with 0%-4.3% among prostitutes 
from other regions. In prostitutes from high prevalence regions, 
HTLV-1 infection was associated with increasing age, active 
syphilis and HIV infection. Among women from low-prevalence 
regions, no signifi cant differences in the HTLV-1 seroprevalence 
were found between prostitutes (4.3%) and pregnant women 
(3.5%). In 409 prostitutes who were observed for a mean 
duration of 23 months, the incidence of HTLV-1 infection 
was 0.7 per 100 women-years, whereas the incidence of HIV 
infection was 9.8 per 100 women-years. The authors concluded 
that prostitution was not associated with an increased risk of 
HTLV-1 infection in Kinshasa. However, these discrepancies 
might have been at least partially infl uenced by the prevalence 
of other sexually transmitted diseases in the study populations.
Nakashima et al.58 found a signifi cantly higher HTLV-1 
prevalence in prostitutes. Additionally, among subjects with 
sexually transmitted diseases, they observed that female 
prostitutes, female syphilis patients, male patients with non-
gonococcal urethritis, and female gonorrhea patients had 
signifi cantly higher HTLV-l prevalence rates than that observed 
in the patient control group. In Peru, Gotuzzo et al.50 found that 
HTLV-1 seropositivity was signifi cantly correlated with the 
duration of prostitution, inconsistent condom use, the presence 
of antibodies to herpes simplex virus type 2 (HSV-2), and prior 
Chlamydia trachomatis infections.
Murphy et al.51 studied 1,977 patients who visited clinics 
for the treatment of sexually transmitted diseases and found an 
overall HTLV-1 seroprevalence rate of 5.7%. The prevalence of 
HTLV-1 was higher in female patients with sexually transmitted 
diseases. The independent risk factors for HTLV-1 infection in 
women included more than ten sexual partners in lifetime and 
a current diagnosis of syphilis. In men, a history of penile sores 
or ulcers and a current diagnosis of syphilis were independent 
risk factors for HTLV-1 infection. Of 1,977 patients, fi ve (0.3%) 
had antibodies to HIV-1, including two with HTLV-1 and HIV-1 
co-infections.
Berini et al.56 estimated the prevalence of HTLV-1/2 
infections and co-infections with HIV, hepatitis B, hepatitis C, 
and Treponema pallidum in fi ve high-risk groups in Argentina. 
In addition, they characterized the epidemiological patterns 
of these infections. The high-risk groups included injection 
drug users, female sex workers, men who engaged in sexual 
intercourse with other men, patients with tuberculosis, and 
patients who attended clinics for sexually transmitted infections. 
The study yielded an overall HTLV-1/2 prevalence rate of 2.7% 
(56/2,055 subjects) (1.3% and 1.4% for HTLV-1 and HTLV-2, 
respectively), which was signifi cantly higher than the prevalence 
rate in healthy adult volunteer blood donors from the same area 
of Buenos Aires (0.03%-0.08%). The prevalence rates of HTLV-1/2 
among female sex workers, patients who sought treatment 
for sexually transmitted infections, and men who engaged in 
sexual intercourse with other men were 2.1%, 1% and 0.4%, 
respectively.
In areas with a low prevalence of HTLV, a London study 
reported that HTLV seropositivity was up to 100-fold greater 
among patients who sought clinical treatment for sexually 
transmitted infections than in non-infected blood donors54. No 
infected individuals in this study reported a history of injection 
drug use or blood transfusion.
HTLV-1 infection is more prevalent among men who 
engage in intercourse with men than among those who engage 
in intercourse with women, most likely because of the large 
numbers of lymphocytes in the gastrointestinal tract and an 
increased risk of mucosal injury during intercourse. The risk 
factors for HTLV-1 infection include older age, a greater number 
of male sexual partners in lifetime, and unprotected receptive 
anal intercourse51-53.
To test for retroviral infections, La Rosa et al.52 performed 
serological analyses in 2,655 Peruvian men who engaged in 
intercourse with other men and who had no history of injection 
drug use. HTLV-1 was detected in 1.8% of the patients, and 
HTLV-2 was detected in 1.1% of the patients. HTLV-1 and 
HTLV-2 were detected in 0.2% of the patients. HIV was detected 
in 12.4% of the patients, and 7.3% of these patients had HTLV 
co-infections. HTLV-1 and HTLV-2 infections were associated 
with high-risk behaviors, syphilis, and HSV-2 infection.
There is evidence of an association between the risk of HTLV 
infection among men who engage in intercourse with other men 
and sexually transmitted diseases, including HIV infection52, 
HSV-2 52,53, and syphilis52,53.
High prevalence rates of HTLV-1 and HTLV-2 were observed 
in immigrant male-to-female transsexual sex workers from 
Latin America. Zehender et al.55 surveyed 393 recent European 
immigrants for HTLV-1 and HTLV-2 infections. Of these 
individuals, 167 were HIV-positive, including 52 male-to-female 
transsexual sex workers, and 226 were HIV-negative pregnant 
women. The HTLV prevalence rate in the HIV-positive group 
was 3.6% compared with 0.9% in the HIV-negative group. Latin 
Americans, particularly those born in Peru, were associated with 
the highest HTLV-1 prevalence in both groups. All of the HIV-1/
HTLV-1 co-infected individuals were male-to-female transsexual 
sex workers; the overall prevalence rate of HTLV-1 infection in 
this group was 11.5%. HTLV-2 was only found in HIV-1-positive 
individuals; these infected subjects were transsexual sex workers 
from Brazil (an overall prevalence of 6.4%).
Roucoux et al.65 observed lower HTLV-1/2 proviral loads 
in patients with sexually acquired infections compared with 
HTLV-1/2-positive index patients who transmitted HTLV, most 
likely because of the small infectious dose that is required for 
the sexual transmission of the virus.
In contrast to other authors, Ishak et al.14 did not fi nd any 
differences in the HTLV-2 infection rates between male and 
female subjects (31.4% vs. 34.2%) in the Kayapo tribe from 
the Brazilian Amazon region. This result is in disagreement 
with the evidence of more effi cient viral transmission from 
males to females. 
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GENITAL EXCRETION AND VIRAL 
TRANSMISSION OF HTLV
HTLV transmission might be infl uenced by several factors, 
including genitourinary HTLV shedding. Many factors are 
associated with HTLV shedding and the HTLV proviral load in 
genital (seminal and vaginal) secretions (Figure 2).
In the vertical transmission of HTLV-1, the proviral load 
in peripheral blood mononuclear cells is correlated with the 
proviral load in breast milk, and higher proviral loads increase 
the risk of HTLV-1 transmission68,69. Similarly, higher proviral 
loads in peripheral blood mononuclear cells might be associated 
with increased shedding of HTLV-1, which increases the risk 
of sexual transmission. 
High HTLV-1 and HTLV-2 proviral loads have been 
reported to increase the risk of male-to-female HTLV-1 
transmission65-66,70. In an investigation of blood donors and 
their stable heterosexual sexual partners, Kaplan et al. reported 
higher circulating proviral loads among seroconcordant couples 
in which the male partner had most likely transmitted the virus 
to his female partner than among couples with non-transmitting 
male partners70.
Stuver et al.66 studied 534 married couples with at least one 
HTLV-1-seropositive spouse. After fi ve years of follow-up, they 
reported that the age of seropositive husbands (up to 60 years) 
was an important factor for HTLV-1 transmission to wives, 
possibly because of an age-related increase in viremia.
Roucoux et al.65 observed higher proviral loads in HTLV-
positive index partners who transmitted HTLV than in HTLV-
positive index partners who did not transmit the virus; however, 
the limited number of detected seroconversions suggested that 
this association was not statistically signifi cant in their cohort. 
In contrast, a signifi cantly lower proviral load was observed in 
newly infected partners, which indicates that low proviral loads 
in newly infected partners might be associated with a small 
infectious dose in the sexual transmission of HTLV.
Higher proviral loads tend to be associated with HAM/
TSP71-75, adult T-cell leukemia-lymphoma76, HTLV-1-associated 
infective dermatitis77, and HTLV-1 uveitis78. HAM/TSP patients 
presented proviral loads in peripheral blood mononuclear cells 
that were 10-fold higher than those in asymptomatic HTLV-1 
carriers71. Additionally, Strongyloides stercoralis infection 
might increase circulating HTLV-1 proviral loads76,79,80. One 
study reported that the proviral loads in HTLV-1 carriers with 
strongyloidiasis were more than fi ve times higher than those 
in HTLV-1-positive individuals without strongyloidiasis, 
most likely because of oligoclonal expansion72. Therefore, 
infl ammatory conditions might recruit lymphocytes to the genital 
tract, where they are infected with HTLV-1 particles. Conditions 
that are associated with an increased number of lymphocytes in 
cervicovaginal secretions and semen might result in an increased 
excretion of infected cells and a consequently higher risk of 
HTLV sexual transmission81,82.
Zunt et al.61 detected cervical shedding of HTLV-1 
deoxyribonucleic acid (DNA) in 68% of 63 HTLV-1- infected 
Peruvian sex workers. HTLV-1 DNA was associated with the 
presence of ≥30 polymorphonuclear cells (PMNs) per 100x 
microscopic fi eld cervical mucus sample. The cervical shedding 
of HTLV DNA was observed in 81% of the samples from women 
with ≥30 PMNs and in 49% of the samples from women with 
<30 PMNs on endocervical gram staining. In addition, shedding 
was associated with grossly visible cervical secretions.
The enrichment of PMNs in cervical mucus might be 
associated with Neisseria gonorrhoeae, C. trachomatis, or 
HSV cervical infections; however, Zunt et al.61 did not fi nd 
statistically signifi cant associations between C. trachomatis 
and N. gonorrhoeae infections, and the presence of HTLV 
DNA was most likely due to the small sample size in the 
study. Co-infections or other conditions that were not tested, 
such as HSV, Treponema pallidum, or Mycoplasma genitalium 
infections, which are known causes of ulcerations and non-
gonococcal cervicitis, might have been associated with the 
observed cervicitis. The authors did not perform colposcopies to 
determine the infl uence of cervical ectopy or other abnormalities 
on HTLV-1 cervical shedding. The results clearly suggest that 
cervicitis might increase HTLV-1 cervical shedding and sexual 
transmission of the virus61.
Higher concentrations of infected lymphocytes in semen 
than in vaginal secretions might be associated with more 
effi cient viral transmission from men to woman. The leukocyte 
cut-off values in fertile men have been reported to vary from 
0.5-1.0×106 PMN leukocytes per mL and from 1-2×106 total 
leukocytes per mL83.
Granulocytes are the most prevalent white blood cells 
(WBCs) in semen (50%-60%), followed by macrophages 
(20%-30%) and T-lymphocytes (2%-5%)83-85; however, the 
range of these subpopulations in the semen of infertile men 
varies widely. Approximately 50% of leukocytes are T cells, 
28% are cluster of differentiation 4 (CD4) T lymphocytes, and 
11% are cluster of differentiation 8 (CD8) T lymphocytes86. 
These differences might be attributed to differential exudate 
leukocyte compositions that are related to the type of invading 
pathogen or irritant, which varies among populations according 
to the prevalence of certain infections and exposure to toxic 
environmental irritants86.
HTLV-infected lymphocytes, particularly those in sperm, are 
considered the primary vectors of sexual transmission; however, 
the concurrence of genital infections and sexually transmitted 
diseases might facilitate viral transmission because these 
conditions expose target cells through genitomucosal lesions87.
Ulcerative sexually transmitted diseases, such as syphilis, 
HSV-2, and chancroid, cause lesions that result in the breakdown 
of mucosal integrity and recruit activated target cells, including 
an enriched population of cells that carry CD4 cell receptors. 
Additionally, these sexually transmitted diseases lead to a 
cascade of pro-infl ammatory cytokines that recruit infl ammatory 
cells to the genital tract83. The presence of other infl ammation-
causing sexually transmitted diseases, such as N. gonorrhoeae, 
C. trachomatis, and T. vaginalis, results in the recruitment of 
infl ammatory cells88 and potentiates HTLV acquisition and 
transmission. 
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The presence of anti-Tax antibodies is associated with 
the sexual transmission of HTLV-1. Using a Western blot 
assay with a recombinant Tax protein as the antigen, Chen 
et al.89 tested serum samples from married couples who were 
serologically discordant or concordant for HTLV-1. The results 
revealed that 24 of 32 (75%) men within the concordant group 
(in which both the husband and wife were HTLV-1 carriers) 
had anti-Tax antibodies, whereas 5 of 18 (27.8%) men in the 
discordant group (in which the husband was a carrier and the 
wife was seronegative for HTLV-1) were positive for anti-Tax 
antibodies. The spouses of the fi ve seroconverters (four women 
and one man) had anti-Tax antibodies, whereas 23 (50%) of 
46 age-matched, randomly selected HTLV-1 carriers from the 
discordant couple group had anti-Tax antibodies. When the 
data were analyzed according to gender, all of the husbands 
of the female seroconverters had anti-Tax antibodies, and this 
prevalence was signifi cantly higher than the prevalence of anti-
Tax antibodies in men who did not transmit the virus to their 
spouses during the follow-up period (p=0.017).
Moriuichi et al.90 demonstrated that seminal fl uid could 
enhance HTLV-1 replication and transmission by the 
transactivation of the HTLV-1 long terminal repeat promoter, 
which results from several bioactive factors in seminal fl uid. 
Previously, these authors had hypothesized that prostaglandins 
(PGs), which are plentiful in breast milk and seminal fl uid, might 
be involved in HTLV-1 transmission. They subsequently found 
that the virus interacted with and benefi tted from PGs as follows: 
prostaglandin E2 (PGE2) enhanced HTLV-1 replication by up-
regulating the HTLV-1 long terminal repeat (LTR) promoter, 
and HTLV-1 Tax transactivated a promoter for ciclo-oxigenase-2 
(COX-2), a PG synthetase, which stimulated the production of 
PGE2. This synergistic mechanism most likely accelerates viral 
transmission through seminal fl uid91.
 A DECREASE IN HTLV-1 VIRAL SHEDDING 
AND A REDUCTION IN SPREAD 
THROUGH NATURAL BARRIERS
The rate of sexual HTLV transmission might be infl uenced 
by factors that reduce viral excretion or hinder viral passage 
through natural barriers. 
Belec et al.92 tested paired sera, saliva, and cervicovaginal 
secretions from 17 HTLV-1-infected women and found that 
HTLV-1 excretion elicits a weak local immune response to 
the infection, which might limit HTLV-1 transmission via 
cervicovaginal secretions. HTLV-1 DNA was detected in 24% of 
the saliva secretion samples, 20% of the cervicovaginal secretion 
samples, and all of the samples from patients who were positive 
for the local synthesis of HTLV-1-specifi c immunoglobulin 
A (IgA) or immunoglobulin G (IgG). Additionally, HTLV-1 
antiserum, which contains high titers of anti-Env neutralizing 
antibodies, was a potent inhibitor in most of the assays, 
indicating that neutralizing antibodies in patient sera might play 
an important role in protection against HTLV-1 transmission, 
particularly if the antibodies are also at high titers in vaginal 
secretions. The presence of these antibodies might help limit 
HTLV-1 transmission via cervicovaginal secretions93.
To test the hypothesis that human foreskin susceptibility 
to HIV-1 infection is associated with the number of HIV-1 
target cells and the expression of HIV-1 co-receptors, Patterson 
et al.94 quantifi ed CD4+ T cells, macrophages, and Langerhans 
cells (LCs) in foreskin tissue from pediatric and adult patients 
without histories of sexually transmitted disease. The authors 
used cervical biopsies from HIV-1-seronegative women as 
controls and found that the adult foreskin mucosa contained 
higher mean proportions of CD4+ T cells (22.4%), macrophages 
(2.4%), and LCs (11.5%) than both the foreskin mucosa 
of children (4.9%, 0.3%, and 6.2%) and cervical mucosa 
(6.2%, 1.4%, and 1.5%). Additionally, they observed that the 
number of target cells increased with patient age. The highest 
proportions of CD4+ T cells and LCs occurred in patients with 
a history of infection with balanitis, C. trachomatis, or genital 
ulcers. The majority of T cells were found in the submucosa rather 
than in the external foreskin mucosa. These results indicate that 
a decrease in the number of HIV-1 target cells and an increase in 
external foreskin keratinization reduce susceptibility to HIV-1 
infection in the outer foreskin compared with the inner surface.
Despite the lower effi ciency of HTLV-1 infection compared 
with HIV infection, these data could theoretically be applied 
to HTLV-1. Similar to HIV, HTLV uses CD4 as the target 
cell; therefore, foreskin circumcision might have a potential 
protective effect against HTLV infection.
Studies on candidate topical microbicides suggest that 
these agents might reduce HTLV-1 sexual transmission93 and 
reduce circulating proviral loads without affecting host immune 
systems; topical microbicides are potential therapeutic agents for 
the prevention and treatment of HTLV-1-associated diseases95.
Approximately 80% of viral infections are initiated at 
mucosal surfaces, and virus particles could be retained on cell 
surfaces in a biofi lm-like structure before transfer to cell-cell 
contact regions; therefore, the role of extracellular matrix 
components in virus transmission requires further study96.
Antiretroviral therapy is not used clinically to reduce the 
risk of HTLV transmission, such as in cases that result from 
occupational accidents, vertical transmission, or sexual violence. 
Few studies have evaluated potential therapies for pre- or post-
exposure prophylaxis against HTLV infection. Further studies 
are required to evaluate drug and treatment protocol effi cacies 
for the prevention or reduction of viral transmission and cell-cell 
spread and to determine the treatment effects on HTLV-1 levels 
in genital secretions. The development of therapies to prevent 
horizontal and vertical transmission of HTLV is particularly 
important for discordant couples who wish to have children.
According to Zihlmann97, the reproductive decisions of 
couples are complex, and no simple guidelines are available 
to reduce the transmission risks for serodiscordant couples. 
The study by Zihlmann highlighted the recommendations 
from the Guia de Manejo Clínico do HTLV do Ministério da 
Saúde of Brazil and the recommendations by the Centers for 
Disease Control and Prevention in the United States. These 
recommendations suggest that in cases in which a sexual partner 
is negative, the couple should be advised to use condoms; 
however, no recommendations are indicated in cases in which 
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both sexual partners are positive. In addition, serodiscordant 
couples are advised to use condoms outside the fertile period; 
however, condom use might be excluded during attempts to 
conceive.
The Ministry of Health of Brazil has recommended semen 
viral load determination and sperm washing as strategies 
to reduce the risks of sexual HIV transmission for people 
who live and coexist with human immunodefi ciency virus/
acquired immunodefi ciency syndrome (HIV/AIDS) and wish 
to conceive98. However, no comparable studies have measured 
the predictive value of the HTLV proviral load in semen in 
determining the risk of sexual HTLV transmission.
In HTLV infection, cell-to-cell contact and Tax-induced 
clonal expansion of infected cells are the primary modes of 
virus replication, which causes diffi culty in detection of the virus 
during the viremic stage. Cabral et al.99 recently reported the 
detection of free HTLV-1 RNA in the plasma from asymptomatic 
HTLV-1 carriers and HAM/TSP patients. In this study, real-
time polymerase chain reaction (PCR) was performed using 
DNA, which was isolated from 150 plasma samples from 123 
HTLV-1 asymptomatic carriers and 27 HAM/TSP-positive 
patients. Twelve (8%) samples had detectable HTLV-1 DNA, 
including six (4%) samples from asymptomatic HTLV-1 carriers 
and 14 (26%) samples from HAM/TSP patients (p<0.005). 
Additionally, a subset of 40 HTLV-1 ribonucleic acid (RNA) 
samples was amplifi ed using nested PCR to increase the HTLV-1 
detection sensitivity and specifi city. Of these samples, seven 
were excluded from the analysis. Of the 33 remaining samples 
that were retro-transcribed to complementary DNA (cDNA) and 
amplifi ed using nested PCR, six (18%) samples were positive 
for plasma proviral RNA. This study found that free RNA 
could be detected in plasma samples among HTLV-1-infected 
subjects regardless of the clinical status, which suggests new 
strategies for HTLV replication. However, the effect of this 
phenomenon the routes of HTLV transmission, particularly 
sexual transmission, remains to be determined. This mode of 
replication might infl uence HTLV transmission rates, which 
are signifi cantly higher in women than in men research that 
address these critical knowledge gaps might contribute to the 
prevention of HTLV transmission and to improved care for 
HTLV-infected individuals. 
Japanese efforts have demonstrated that preventive measures, 
such as screening blood bank donations, counseling serodiscordant 
couples, and abstinence from breastfeeding by carrier mothers, 
might reduce the prevalence of HTLV. Several years after the 
commencement of the ATL Prevention Program Nagasaki 
in 1987, a sharp decline in the prevalence of HTLV carriers 
(from 20%-25% to 4%) was observed in the Nagasaki population30.
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